Study Evaluating the Effects of Avanafil on Semen Parameters
This study is currently recruiting participants.
Verified May 2013 by VIVUS, Inc.
Sponsor:
VIVUS, Inc.
Information provided by (Responsible Party):
VIVUS, Inc.
ClinicalTrials.gov Identifier:
NCT01768676
First received: January 11, 2013
Last updated: May 6, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether avanafil will affect different aspects of sperm production.
| Condition | Intervention | Phase |
|---|---|---|
|
Erectile Dysfunction |
Drug: avanafil Drug: Placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction |
Resource links provided by NLM:
MedlinePlus related topics:
Erectile Dysfunction
Drug Information available for:
Avanafil
U.S. FDA Resources
Further study details as provided by VIVUS, Inc.:
Primary Outcome Measures:
- Percentage of subjects with a greater than or equal to 50% decrease in sperm concentration from baseline to week 26 [ Time Frame: baseline to week 26 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 220 |
| Study Start Date: | December 2012 |
| Estimated Study Completion Date: | February 2014 |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: avanafil
100 mg
|
Drug: avanafil
100 mg
Other Names:
|
|
Placebo Comparator: Placebo
placebo
|
Drug: Placebo |
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Provide written informed consent
- Able to produce semen samples without requiring therapy (PDE5 inhibitors, over-the-counter (OTC) medication, and/or herbal supplements) for erectile dysfunction
- Be medically healthy (no clinically significant screening results for medical history, electrocardiogram (ECG), laboratory studies, physical examination, etc.) in the opinion of the investigator
- Be willing and able to comply with all study requirements
Exclusion Criteria:
- An International Index of Erectile Function (IIEF) erectile function domain score of less than 17;
- History of infertility, vasectomy, testicular mass, testicular trauma, testicular abnormality (including size), radiation to the testis, previous pelvic surgery, cryotherapy of the prostate, known sperm defect, or retrograde ejaculation, or cryptorchidism;
- Resting heart rate <45 or >90 beats per minute at screening (3 rechecks permitted);
- Screening systolic blood pressure <90 or >140 mmHg and/or diastolic blood pressure <50 or >90 mmHg (3 rechecks permitted);
- High serum FSH (>18.0 mIU/mL), high serum LH (>18 mIU/mL), or low serum testosterone (< 270 ng/dL, early morning collection) on screening;
- AST or ALT >2.0 x ULN or other evidence of significant hepatic impairment;
- Prostate specific antigen (PSA) level ≥4 ng/mL at screening;
- Individuals who perform rotating shift work during the course of the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01768676
Contacts
| Contact: Dan Nobles | 910-558-3914 | dan.nobles@ppdi.com |
Locations
| United States, Alabama | |
| Research Facility | Recruiting |
| Huntsville, Alabama, United States | |
| United States, California | |
| Research Facility | Recruiting |
| LA, California, United States | |
| Research Facility | Recruiting |
| San Diego, California, United States | |
| United States, Colorado | |
| Research Facility | Recruiting |
| Parker, Colorado, United States | |
| United States, Florida | |
| Research Facility | Recruiting |
| Aventura, Florida, United States | |
| United States, Indiana | |
| Research Facility | Recruiting |
| Carmel, Indiana, United States | |
| United States, Louisiana | |
| Research Facility | Recruiting |
| New Orleans, Louisiana, United States | |
| Research Facility | Recruiting |
| Shreveport, Louisiana, United States | |
| United States, Missouri | |
| Research Facility | Recruiting |
| Kansas City, Missouri, United States | |
| United States, New York | |
| Research Facility | Recruiting |
| Albany, New York, United States | |
| Research Facility | Recruiting |
| New York, New York, United States | |
| United States, Ohio | |
| Research Facility | Recruiting |
| Cincinnati, Ohio, United States | |
| United States, Pennsylvania | |
| Research Facility | Recruiting |
| Bala Cynwyd, Pennsylvania, United States | |
| United States, Tennessee | |
| Research Facility | Recruiting |
| Knoxville, Tennessee, United States | |
| United States, Texas | |
| Research Facility | Recruiting |
| San Antonio, Texas, United States | |
Sponsors and Collaborators
VIVUS, Inc.
More Information
Additional Information:
Related Info 
No publications provided
| Responsible Party: | VIVUS, Inc. |
| ClinicalTrials.gov Identifier: | NCT01768676 History of Changes |
| Other Study ID Numbers: | TA-401 |
| Study First Received: | January 11, 2013 |
| Last Updated: | May 6, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by VIVUS, Inc.:
|
healthy male |
Additional relevant MeSH terms:
|
Erectile Dysfunction Sexual Dysfunction, Physiological Genital Diseases, Male |
Sexual Dysfunctions, Psychological Sexual and Gender Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 19, 2013